AVALIDE NEWS HIGHLIGHTS Media Articles Related to Avalide (Irbesartan / Hydrochlorothiazide)
New Product For Pfizer Specialty Takes Pulmonary Arterial Hypertension To Heart
Source: Health News from Medical News Today [2009.07.02]
Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELIN® (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA/WHO Functional Class III symptoms to improve exercise ability.
Rat Model Of Hepatic Encephalopathy And Prehepatic Portal Hypertension
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2009.06.30]
A research article published in the World Journal of Gastroenterology refers. The research team lead by Dr. Gabriela Beatriz Acosta, observed that the activity of GS was increased in the hippocampus in PH rats. There was a significant decrease in glutamate uptake in both brain areas, which was more marked in the hippocampus. The decrease in glutamate uptake might be caused by deficient transport function and persistent glutamate activity, which is not metabolized.
Sporadic Spikes in Blood Pressure Hike Chances of Hypertension
Source: MedicineNet Cholesterol Specialty [2009.06.30]
Title: Sporadic Spikes in Blood Pressure Hike Chances of Hypertension
Category: Health News
Created: 6/30/2009 7:00:00 AM
Last Editorial Review: 6/30/2009
White-Coat Hypertension Not Benign
Source: MedicineNet Exercise and Activity Specialty [2009.06.30]
Title: White-Coat Hypertension Not Benign
Category: Health News
Created: 6/30/2009
Last Editorial Review: 6/30/2009
'White-Coat' Hypertension May Persist Over Time (CME/CE)
Source: MedPage Today Cardiovascular [2009.06.29]
SAN FRANCISCO (MedPage Today) -- Sporadic hypertension, whether just in the doctor's office or only occasionally at home, substantially increases risk of later sustained hypertension, researchers found.
Published Studies Related to Avalide (Irbesartan / Hydrochlorothiazide)
Raltegravir. [2008]
* Raltegravir, the first in a new class of orally administered HIV type-1 (HIV-1) integrase inhibitors, selectively inhibits the strand transfer activity of HIV-1 and its integration into human DNA, a key stage in retroviral propagation, thereby limiting viral replication and the infection of new cells... The incidence of mild to moderate adverse events was similar in the raltegravir and placebo arms of the two randomized trials.
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. [2006.12]
Severe hypertension is difficult to control. This prospective, randomized, double-blind, active-controlled, multicenter trial compared efficacy and safety of once-daily irbesartan/hydrochlorothiazide [generic for Avalide] (HCTZ) combination therapy with irbesartan monotherapy in severe hypertension... Greater and more rapid BP reduction with irbesartan/HCTZ was achieved without additional side effects.
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. [2006.04]
The IrbesartaN/hydroChlorothiazide [generic for Avalide] (HCTZ) bLood pressUre reductionS In diVErse patient populations (INCLUSIVE) trial was a multicenter, prospective, open-label, single-arm study evaluating the efficacy and safety of irbesartan/HCTZ fixed combinations in patients > or = 18 years old with uncontrolled systolic blood pressure (SBP, 140-159 mmHg; 130-159 mmHg for type-2 diabetes mellitus patients) after > or = 4 weeks of antihypertensive monotherapy...
Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. [2005.11]
This study examined whether the greater anti-hypertensive efficacy of irbesartan monotherapy over losartan monotherapy extends to the respective fixed-dose combinations with hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension. Patients were treated with either irbesartan 150 mg/HCTZ 12.5 mg or losartan 50 mg/HCTZ 12.5 mg over a 4-week period.
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. [2004.10]
The aim of this double-blind, double-dummy, parallel group study was to compare the effects of delapril-manidipine combination vs a irbesartan-hydrochlorothiazide combination on plasma tissue plasminogen activator (t-PA) and plasmogen activator inhibitor type I (PAI-l) activities in hypertensive patients with type II diabetes mellitus... In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it.
Clinical Trials Related to Avalide (Irbesartan / Hydrochlorothiazide)
Adalat ® XL® vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients [Recruiting]
The study consists of a 12 week run-in period when all subjects are stabilized on a single
dose of Avalide (300 mg/12. 5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends,
subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC for
18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat
XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit will be
done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The
purpose of this study is to compare the change in proteinuria, through a urine test, while
taking study drug until high blood pressure (BP) is reduced to near normal levels in study
subjects with diabetic nephropathy and hypertension.
AMISH : Aprovel for Management of Isolated Systolic Hypertension [Completed]
To compare the antihypertensive efficacy and tolerability of irbesartan and
irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus
hydrochlorothiazide in the treatment of isolated systolic hypertension.
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients [Recruiting]
I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients [Completed]
- To evaluate control rate of Blood Pressure ≤ 140/90 mm Hg in non-diabetic patients, and
≤ 130/80 mm Hg in diabetic patients.
- To determine percentage of patients achieving blood pressure control according to their
profile (naïve, switch, patient history, etc…) at the end of the trial.
I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy [Recruiting]
- To evaluate Blood Pressure (BP) reduction to the targeted values (BP ≤ 140/90 mm Hg in
non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients).
- To emphasize and to evaluate the benefit of Irbesartan in the reduction of left
ventricular mass index in hypertensive patients with left ventricular hypertrophy.
- To demonstrate safety of Irbesartan in this population.
|
